APP and Alzheimer disease: Likewise, oral treatment of APPswe/PS1dE9 (APP/PS1) mice, as AD model mice with epigallocatechin-3-gallate nanoparticles, significantly improved spatial learning and memory by decreasing neuroinflammation, amyloid β (Aβ) plaque burden, and cortical levels of soluble and insoluble Aβ(1-42) peptide [165].